Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris

Next Previous
Trial Profile

An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilzabrutinib (Primary) ; Prednisone; Rituximab
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms Believe-PV
  • Sponsors Principia Biopharma

Most Recent Events

  • 03 May 2021 Results (n=27) assessing efficacy and safety of oral rilzabrutinib in patients with pemphigus vulgaris, published in the British Journal of Dermatology.
  • 12 Jun 2020 Results published in the Principia Biopharma Media Release.
  • 12 Jun 2020 According to a Principia Biopharma media release, positive data from the Part B of the study was presented as part of the virtual Late-Breaker session of the American Academy of Dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top